Mela Sciences Inc. (NASDAQ:SSKN) has received a consensus broker rating score of 1.00 (Strong Buy) from the one brokers that cover the stock, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus price target of $2.00 for the company and are anticipating that the company will post ($0.10) earnings per share for the current quarter, according to Zacks. Zacks has also given Mela Sciences an industry rank of 107 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research downgraded Mela Sciences from a “buy” rating to a “hold” rating in a report on Saturday, June 11th.
Mela Sciences (NASDAQ:SSKN) opened at 0.51 on Monday. The firm’s market capitalization is $5.43 million. Mela Sciences has a 52-week low of $0.48 and a 52-week high of $1.53. The firm’s 50-day moving average is $0.58 and its 200-day moving average is $0.73.
Mela Sciences (NASDAQ:SSKN) last posted its earnings results on Thursday, August 11th. The medical device company reported ($0.23) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.10) by $0.13. Mela Sciences had a negative return on equity of 2.84% and a negative net margin of 32.47%. On average, equities analysts expect that Mela Sciences will post ($0.27) earnings per share for the current year.
An institutional investor recently bought a new position in Mela Sciences stock. BlackRock Institutional Trust Company N.A. purchased a new position in shares of Mela Sciences Inc. (NASDAQ:SSKN) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 322,637 shares of the medical device company’s stock, valued at approximately $305,000. BlackRock Institutional Trust Company N.A. owned about 3.17% of Mela Sciences as of its most recent SEC filing. 24.20% of the stock is owned by hedge funds and other institutional investors.
Mela Sciences Company Profile
STRATA Skin Sciences, Inc, formerly MELA Sciences, Inc, is a medical technology company. The Company is engaged in developing and commercializing products for the diagnosis and treatment of dermatological disorders. The Company has three segments: Dermatology Recurring Procedures, Dermatology Procedures Equipment and Dermatology Imaging.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mela Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mela Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.